A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults

Coronary Artery Disease

Volumn 25, Issue 4, 2014, Pages 360-363

  Ades, Philip A ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

atherosclerotic risk; cardiac prevention; cholesterol management; clinical guidelines

Indexed keywords

COLESTIPOL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; BIOLOGICAL MARKER; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG HYPERSENSITIVITY; HUMAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; TITRIMETRY; ATHEROSCLEROSIS; BLOOD; CARDIOLOGY; COMPLICATION; DECISION SUPPORT SYSTEM; EVIDENCE BASED MEDICINE; HYPERCHOLESTEROLEMIA; MEDICAL SOCIETY; PATIENT SELECTION; RISK FACTOR; STANDARDS; TREATMENT OUTCOME; UNITED STATES;

AMERICAN HEART ASSOCIATION; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOLOGY; CHOLESTEROL; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; HUMANS; HYPERCHOLESTEROLEMIA; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84899939891     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000086     Document Type: Article

References (15)

1. National Cholesterol Education Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421
2. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 2013 [Epub ahead of print]
3. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013; 382:1762-1765
4. Blair SN, Kampert JB, Kohl HW III, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA 1996; 276:205-210
5. Dhaliwal SS, Welborn TA. Central obesity and multivariable cardiovascular risk as assessed by the Framingham prediction scores. Am J Cardiol 2009; 103:1403-1407
6. Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease. JAMA 2013; 310:2451-2452
7. Rembold CM. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. J Fam Pract 1996; 42:577-586
8. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010; 95:2015-2022
9. [No authors listed]. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364
10. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245
11. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267
12. Genest J. High-density lipoprotein and residual cardiovascular risk: de minimis non curat medicus or the COURAGE to be SMART? J Am Coll Cardiol 2013; 62:1842-1844
13. Canner PL, Berge KG,Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255
14. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298
15. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al. Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008; 101:1689-1693.